Document is current
Any future updates will be listed below
-
Authors
Gotthardt, Michael https://orcid.org/0000-0003-1788-3172
Badillo-Lisakowski, Victor https://orcid.org/0000-0001-5906-2589
Parikh, Victoria Nicole
Ashley, Euan https://orcid.org/0000-0001-9418-9577
Furtado, Marta
Carmo-Fonseca, Maria https://orcid.org/0000-0002-3402-7143
Schudy, Sarah
Meder, Benjamin
Grosch, Markus
Steinmetz, Lars
Crocini, Claudia
Leinwand, Leslie https://orcid.org/0000-0003-1470-4810
- License Information
-
More Information
Article History
Accepted: 9 December 2022
First Online: 18 January 2023
Competing interests
: M. Gotthardt has a consultancy agreement with River BioMedics and has received speaker honoraria from Bayer. V.N.P. reports a sponsored research agreement with BioMarin and consulting relationships with Constantiam and viz.ai. E.A. reports sponsored research from Bristol Myers Squibb, has ownership interest in DeepCell, Nuevocor and Personalis, and is a board member of AstraZeneca. M.C.-F. is a cofounder and scientific adviser of GenoMed, a molecular diagnosis company. B.M. holds stocks in biotech and pharma, has received speaker honoraria from Bayer, Bristol Myers Squibb, Daiichi Sankyo, Novartis and Pfizer, and is on the Scientific Advisory Boards of Bristol Myers Squibb/Myokardia and Fleischhacker. L.S. is a co-founder of SOPHiA Genetics, as well as co-founder and board member of LevitasBio and Recombia Biosciences, and receives research support from GlaxoSmithKline. L.L. has sponsored research agreements from Bristol Myers Squibb and Edgewise Therapeutics, and is on the scientific advisory boards of Bristol Meyers Squibb/MyoKardia and Edgewise Therapeutics. The other authors declare no competing interests.
